Theracryf (TCF) Share Price, News & Analysis

Company Overview

TheraCryf plc is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. Formerly Evgen Pharma plc, the Company acquired Chronos Therapeutics in April 2024. TheraCryf, the new name for the Group, reflects a wider mission and broader portfolio. The Company’s clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos’ neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.

Key Stats

• Today's Range: 0.25 to 0.25
• 50-Day Range: 0.20 to 0.29
• 52-Week Range: 0.20 to 1.25
• Volume: 118,218 shs
• Average Volume: 3.26 million shs
• Market Capitalization: £1.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TCF Stock Analysis - Frequently Asked Questions

How have TCF shares performed this year?

Theracryf's stock was trading at GBX 0.54 on January 1st, 2025. Since then, TCF shares have decreased by 54.1% and is now trading at GBX 0.25.
View the best growth stocks for 2025 here.

How were Theracryf's earnings last quarter?

Theracryf Plc (LON:TCF) released its quarterly earnings data on Thursday, November, 28th. The company reported ($29.00) earnings per share for the quarter. Theracryf had a negative trailing twelve-month return on equity of 99.97% and a negative net margin of 792.17%.

How do I buy shares of Theracryf?

Shares of TCF stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Company Calendar

• Last Earnings: 11/28/2024
• Today: 4/29/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Banking
• Current Symbol: LON:TCF
• CIK: N/A
• Web: theracryf.com
• Phone: 44-1625-315-090
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (1.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-5,447,566.69
• Net Margins: -792.17%
• Pretax Margin: N/A
• Return on Equity: -99.97%
• Return on Assets: -48.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.20
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: £687,674.98
• Price / Sales: 1.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: GBX 0.85 per share
• Price / Book: 0.29

Miscellaneous

• Outstanding Shares: 477,357,778
• Free Float: N/A
• Market Cap: £1.18 million
• Optionable: N/A
• Beta: 1.42